273 related articles for article (PubMed ID: 30576636)
1. Pharmacokinetic, biologic and epidemiologic differences in MPA- and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in women.
Heffron R; Achilles SL; Dorflinger LJ; Hapgood JP; Kiarie J; Polis CB; Steyn PS
Contraception; 2019 Apr; 99(4):199-204. PubMed ID: 30576636
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Female Genital Tract Cytokine and Microbiota Signatures Induced by Initiation of Intramuscular DMPA and NET-EN Hormonal Contraceptives - a Prospective Cohort Analysis.
Dabee S; Tanko RF; Brown BP; Bunjun R; Balle C; Feng C; Konstantinus IN; Jaumdally SZ; Onono M; Nair G; Palanee-Phillips T; Gill K; Baeten JM; Bekker LG; Passmore JS; Heffron R; Jaspan HB; Happel AU
Front Immunol; 2021; 12():760504. PubMed ID: 34956191
[TBL] [Abstract][Full Text] [Related]
3. Misreporting contraceptive use and the association of peak study progestin levels with weight and BMI among women randomized to the progestin-only injectable contraceptives DMPA-IM and NET-EN.
Avenant C; Bick AJ; Skosana SB; Dlamini S; Balakrishna Y; Moliki JM; Singata-Madliki M; Hofmeyr GJ; Smit J; Beksinska M; Beesham I; Seocharan I; Batting J; Chen PL; Storbeck KH; Africander D; Hapgood JP
PLoS One; 2023; 18(12):e0295959. PubMed ID: 38134043
[TBL] [Abstract][Full Text] [Related]
4. Long-acting hormonal contraceptives for women.
Garza-Flores J; Hall PE; Perez-Palacios G
J Steroid Biochem Mol Biol; 1991; 40(4-6):697-704. PubMed ID: 1958567
[TBL] [Abstract][Full Text] [Related]
5. Effects of injectable contraception with depot medroxyprogesterone acetate or norethisterone enanthate on estradiol levels and menstrual, psychological and behavioral measures relevant to HIV risk: The WHICH randomized trial.
Singata-Madliki M; Smit J; Beksinska M; Balakrishna Y; Avenant C; Beesham I; Seocharan I; Batting J; Hapgood JP; Hofmeyr GJ
PLoS One; 2024; 19(3):e0295764. PubMed ID: 38530848
[TBL] [Abstract][Full Text] [Related]
6. The contraceptive medroxyprogesterone acetate, unlike norethisterone, directly increases R5 HIV-1 infection in human cervical explant tissue at physiologically relevant concentrations.
Ray RM; Maritz MF; Avenant C; Tomasicchio M; Dlamini S; van der Spuy Z; Hapgood JP
Sci Rep; 2019 Mar; 9(1):4334. PubMed ID: 30867477
[TBL] [Abstract][Full Text] [Related]
7. Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.
Noguchi LM; Richardson BA; Baeten JM; Hillier SL; Balkus JE; Chirenje ZM; Bunge K; Ramjee G; Nair G; Palanee-Phillips T; Selepe P; van der Straten A; Parikh UM; Gomez K; Piper JM; Watts DH; Marrazzo JM;
Lancet HIV; 2015 Jul; 2(7):e279-87. PubMed ID: 26155597
[TBL] [Abstract][Full Text] [Related]
8. WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility.
Contraception; 1982 Jan; 25(1):1-11. PubMed ID: 6460593
[TBL] [Abstract][Full Text] [Related]
9. Hormonal contraceptive use and women's risk of HIV acquisition: priorities emerging from recent data.
Ralph LJ; Gollub EL; Jones HE
Curr Opin Obstet Gynecol; 2015 Dec; 27(6):487-95. PubMed ID: 26536211
[TBL] [Abstract][Full Text] [Related]
10. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
Swenson I; Khan AR; Jahan FA
Contraception; 1980 Mar; 21(3):207-15. PubMed ID: 6446442
[TBL] [Abstract][Full Text] [Related]
11. Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4/CD8 ratios and CCR5 levels.
Maritz MF; Ray RM; Bick AJ; Tomasicchio M; Woodland JG; Govender Y; Avenant C; Hapgood JP
PLoS One; 2018; 13(4):e0196043. PubMed ID: 29698514
[TBL] [Abstract][Full Text] [Related]
12. Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception.
Draper BH; Morroni C; Hoffman M; Smit J; Beksinska M; Hapgood J; Van der Merwe L
Cochrane Database Syst Rev; 2006 Jul; (3):CD005214. PubMed ID: 16856087
[TBL] [Abstract][Full Text] [Related]
13. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis.
Morrison CS; Chen PL; Kwok C; Baeten JM; Brown J; Crook AM; Van Damme L; Delany-Moretlwe S; Francis SC; Friedland BA; Hayes RJ; Heffron R; Kapiga S; Karim QA; Karpoff S; Kaul R; McClelland RS; McCormack S; McGrath N; Myer L; Rees H; van der Straten A; Watson-Jones D; van de Wijgert JH; Stalter R; Low N
PLoS Med; 2015 Jan; 12(1):e1001778. PubMed ID: 25612136
[TBL] [Abstract][Full Text] [Related]
14. Progestin-only injectables offer many advantages.
Finger WR
Netw Res Triangle Park N C; 1995 Jun; 15(4):16-20. PubMed ID: 12289828
[TBL] [Abstract][Full Text] [Related]
15. Vaginal bleeding disturbances associated with the discontinuation of long-acting injectable contraceptives. From the World Health Organization Special Programme for Research, Development, and Research Training in Human Reproduction; Task Force on Long-acting Systemic Agents for the Regulation of Fertility.
Gray RH; Parker RA; Diethelm P
Br J Obstet Gynaecol; 1981 Mar; 88(3):317-21. PubMed ID: 7008825
[TBL] [Abstract][Full Text] [Related]
16. Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence.
Polis CB; Phillips SJ; Curtis KM; Westreich DJ; Steyn PS; Raymond E; Hannaford P; Turner AN
Contraception; 2014 Oct; 90(4):360-90. PubMed ID: 25183264
[TBL] [Abstract][Full Text] [Related]
17. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review.
Dragoman MV; Gaffield ME
Contraception; 2016 Sep; 94(3):202-15. PubMed ID: 26874275
[TBL] [Abstract][Full Text] [Related]
18. Statement on injectable contraception.
International Planned Parenthood Federation IPPF
IPPF Med Bull; 1982 Dec; 16(6):3-4. PubMed ID: 12338511
[TBL] [Abstract][Full Text] [Related]
19. Effect of injectable progestin-only contraceptives, depot medroxyprogesterone acetate and norethisterone enanthate, on cytokine production during T-cell activation.
Matubu AT; Hillier SL; Meyn LA; Stoner KA; Mhlanga F; Mbizvo M; Maramba A; Chirenje ZM; Achilles SL
Am J Reprod Immunol; 2021 Jul; 86(1):e13405. PubMed ID: 33609312
[TBL] [Abstract][Full Text] [Related]
20. Effect of long-acting progestagen-only injectable contraceptives on carbohydrate metabolism and its hormonal profile.
Fahmy K; Abdel-Razik M; Shaaraway M; al-Kholy G; Saad S; Wagdi A; al-Azzony M
Contraception; 1991 Oct; 44(4):419-30. PubMed ID: 1836754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
